Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer

SIMPLE SUMMARY: Treatment of non-resectable metastatic colorectal cancer (mCRC) involves chemotherapy based on 5-fluorouracil, oxaliplatin and irinotecan and monoclonal antibodies targeting VEGF or EGFR. After an initial progression, it is usual to change the chemotherapy regimen and targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellio, Hélène, Bertaut, Aurélie, Hervieu, Alice, Zanetta, Sylvie, Hennequin, Audrey, Vincent, Julie, Palmier, Rémi, Bengrine-Lefevre, Leila, Ghiringhelli, François, Fumet, Jean-David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582415/
https://www.ncbi.nlm.nih.gov/pubmed/34771635
http://dx.doi.org/10.3390/cancers13215472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582415/
https://www.ncbi.nlm.nih.gov/pubmed/34771635
http://dx.doi.org/10.3390/cancers13215472

Ejemplares similares